Pruritus - Pipeline Review, H1 2020
Pruritus - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2020, provides an overview of the Pruritus (Dermatology) pipeline landscape.
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 5, 13, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Pruritus - Overview
Pruritus - Therapeutics Development
Pruritus - Therapeutics Assessment
Pruritus - Companies Involved in Therapeutics Development
Pruritus - Drug Profiles
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Pruritus, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pruritus - Pipeline by Albireo Pharma Inc, H1 2020
Pruritus - Pipeline by Amgen Inc, H1 2020
Pruritus - Pipeline by AntalGenics SL, H1 2020
Pruritus - Pipeline by AOBiome LLC, H1 2020
Pruritus - Pipeline by Asana BioSciences LLC, H1 2020
Pruritus - Pipeline by Biomimetix JV LLC, H1 2020
Pruritus - Pipeline by Cara Therapeutics Inc, H1 2020
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Pruritus - Pipeline by DermaXon LLC, H1 2020
Pruritus - Pipeline by ELORAC Inc, H1 2020
Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2020
Pruritus - Pipeline by Hydra Biosciences Inc, H1 2020
Pruritus - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pruritus - Pipeline by Kiniksa Pharmaceuticals Ltd, H1 2020
Pruritus - Pipeline by Kolmar Korea Holdings Co Ltd, H1 2020
Pruritus - Pipeline by Lumosa Therapeutics Co Ltd, H1 2020
Pruritus - Pipeline by MC2 Therapeutics AS, H1 2020
Pruritus - Pipeline by Menlo Therapeutics Inc, H1 2020
Pruritus - Pipeline by Neurim Pharmaceuticals Ltd, H1 2020
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1 2020
Pruritus - Pipeline by Peptide Logic LLC, H1 2020
Pruritus - Pipeline by RDD Pharma Ltd, H1 2020
Pruritus - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Pruritus - Pipeline by Roivant Sciences Ltd, H1 2020
Pruritus - Pipeline by Saniona AB, H1 2020
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2020
Pruritus - Pipeline by Shaperon Inc, H1 2020
Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, H1 2020
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2020
Pruritus - Pipeline by Sunny Pharmtech Inc, H1 2020
Pruritus - Pipeline by Teikoku Pharma USA Inc, H1 2020
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H1 2020
Pruritus - Pipeline by Toray Industries Inc, H1 2020
Pruritus - Pipeline by Trevi Therapeutics Inc, H1 2020
Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H1 2020
Pruritus - Pipeline by Vivozon Inc, H1 2020
Pruritus - Dormant Projects, H1 2020
Pruritus - Dormant Projects, H1 2020 (Contd..1), H1 2020
Pruritus - Discontinued Products, H1 2020
List of Figures
Number of Products under Development for Pruritus, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned
Albireo Pharma Inc
Amgen Inc
AntalGenics SL
AOBiome LLC
Asana BioSciences LLC
Biomimetix JV LLC
Cara Therapeutics Inc
Chugai Pharmaceutical Co Ltd
DermaXon LLC
ELORAC Inc
GlaxoSmithKline Plc
Hydra Biosciences Inc
Jiangsu Hengrui Medicine Co Ltd
Kiniksa Pharmaceuticals Ltd
Kolmar Korea Holdings Co Ltd
Lumosa Therapeutics Co Ltd
MC2 Therapeutics AS
Menlo Therapeutics Inc
Neurim Pharmaceuticals Ltd
Patagonia Pharmaceuticals LLC
Peptide Logic LLC
RDD Pharma Ltd
Regeneron Pharmaceuticals Inc
Roivant Sciences Ltd
Saniona AB
Sanwa Kagaku Kenkyusho Co Ltd
Shaperon Inc
Sienna Biopharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Sunny Pharmtech Inc
Teikoku Pharma USA Inc
Tioga Pharmaceuticals Inc
Toray Industries Inc
Trevi Therapeutics Inc
Vanda Pharmaceuticals Inc
Vivozon Inc
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets